-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2022-501817-29-00
5
2018-11-27
High Risk Non-muscle invasive bladder cancer
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-513027-16-00
4
2018-05-28
Resectable mucosal melanomas
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-516601-23-00
5
2017-11-14
Colorectal adenomas
-
2024-513972-16-00
5
2017-01-30
- Resected tumors of sinuses or salivary glands
- Non-operable tumors
-
2024-515846-18-00
7
2016-09-19
Newly diagnosed Diffuse Large B Cell Lymphoma
-
2023-510453-41-00
5
2015-10-26
Castration resistant prostate cancer patients metastatic to bone.
-
2024-515171-35-00
5
2011-07-06
Prostatic adenocarnicoma with high risk of recurrence
-
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
-
2024-516672-16-00
5
2024-02-02
Multiple Sclerosis
-
2024-513576-18-00
5
2020-07-17
Cervical Cancer
-
2025-521029-34-00
4
2025-09-18
Patients with overt hepatic encephalopathy (OHE) and acute decompensat
-
2024-513440-29-00
10
2025-06-25
Sickle cell disease vaso-occlusive crisis
-
2024-513697-22-00
5
2024-11-07
non-small-cell lung cancer
-
2024-513648-27-00
4
2024-10-25
Patients with newly or active diffuse Systemic sclerosis (SSc) at the
-
2024-516408-40-00
9
2024-10-14
Non-resectable hepatocellular carcinoma (HCC)
-
2024-513647-86-00
4
2024-09-09
Patients displaying a non-classified, severe and resistant inflammator
-
2022-502899-23-00
5
2024-04-23
Hepatic Encephalopathy (OHE)
-
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma
-
2023-505413-25-00
3
2024-04-10
Infectious S. aureus endocarditis